Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
(2022), Diabetes, Obesity and Metabolism SURMOUNT-4 Trial Tirzepatide weight regain after discontinuation Aronne et al
4 The weight-loss efficacy of tirzepatide in both diabetic and non-diabetic individuals has been shown in the SURMOUNT trials
Patients often weigh the convenience of wellness IV drips against the long-term cost
In March 2024, CMS issued new guidance stating that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use
Reference: Maher P (2005)
US$ 28.85
US$ 29.96
US$ 26.33
US$ 21.22
US$ 22.06
US$ 26.63
